APC anti-human HLA-A,B,C Antibody

Pricing & Availability
W6/32 (See other available formats)
Regulatory Status
Other Names
Major Histocompatibility Class I, MHC class I
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
Human peripheral blood lymphocytes stained with W6/32 APC
  • W632_APC_072607
    Human peripheral blood lymphocytes stained with W6/32 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
311409 25 tests £94
Check Availability

Need larger quantities of this item?
Request Bulk Quote
311410 100 tests £200
Check Availability

Need larger quantities of this item?
Request Bulk Quote

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type
Host Species
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Hoke ATK, et al. 2021. Cancer Res Commun. 1:127. PubMed
  2. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  3. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  4. Preece R, et al. 2020. Gene Ther. 451:27. PubMed
  5. Zuo J, et al. 2011. J Virol. 85:1604. PubMed
  6. Foucras G, et al. 2011. J Immunol. 187:6564. PubMed
  7. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  8. Charles A, et al. 2021. Oncoimmunology. 10:1916243. PubMed
  9. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  10. Kaseke C, et al. 2021. Cell Reports. 36(2):109378. PubMed
  11. Choi J, et al. 2021. Cell Rep Methods. 1:100084. PubMed
  12. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  13. Hashimoto M, et al. 2015. J Immunol. 95: 4341 - 4350. PubMed
  14. Mitchell K, et al. 2018. J Exp Med. 215:1709. PubMed
  15. Heusinger E, et al. 2018. J Virol. 92:18. PubMed
  16. Kula T, et al. 2019. Cell. 178:1016. PubMed
  17. Zhuang X, et al. 2020. Front Immunol. 2.415972222. PubMed
  18. Bondarenko M, et al. 2021. Cancers (Basel). 13: . PubMed
  19. Ren J, et al. 2022. J Clin Invest. . PubMed
  20. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  21. Madrid A, et al. 2012. J Virol. 86: 8693. PubMed
  22. Bachireddy P, et al. 2020. Sci Transl Med. :12. PubMed
  23. Amabile A et al. 2016. Cell. 167(1):219-232 . PubMed
  24. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  25. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  26. Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed
  27. Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed
  28. Rapiteanu R, et al. 2020. Eur Respir J. :55. PubMed
  29. Shan X et al. 2017. eLife. 6 pii: e25306. PubMed
  30. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  31. Bradley S, et al. 2015. Cancer Immunol Res. 3:602. PubMed
  32. Hashimoto M, et al. 2016. J Immunol. 1832 - 1841. PubMed
  33. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  34. Croft N, et al. 2009. PLoS One. 5:e1000490. PubMed
  35. Amo L, et al. 2022. Front Immunol. 13:835527. PubMed
  36. Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed
  37. Io S, et al. 2021. Cell Stem Cell. 28(6):1023-1039.e13. PubMed
  38. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
  39. Slaine PD, et al. 2021. J Virol. 95:e00453. PubMed
  40. Bear AS, et al. 2021. Nat Commun. 12:4365. PubMed
  41. Lee JH, et al. 2020. Nat Commun. 11:1897. PubMed
  42. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  43. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  44. Sim MJW, et al. 2020. Proc Natl Acad Sci U S A. 117:12826. PubMed
  45. Dheilly E, et al. 2020. Cancer Cell. 37(5):674-689. PubMed
  46. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  47. Alvino VV, et al. 2018. J Am Heart Assoc. 7:e006727. PubMed
  48. Lee PC, et al. 2022. J Clin Invest. 132:. PubMed
  49. Rainho J, et al. 2015. J Virol. 89: 10625 - 10636. PubMed
  50. Joas S, et al. 2018. Nat Commun. 9:902. PubMed
  51. Joas S, et al. 2020. Cell Rep. 30:2261. PubMed
  52. Kimmel E, et al. 2011. Antiviral Res. 90:80. PubMed
  53. Saif J, et al. 2010. Arterioscler Thromb Vasc Biol. 30:1897. PubMed
AB_314878 (BioLegend Cat. No. 311409)
AB_314879 (BioLegend Cat. No. 311410)

Antigen Details

Ig superfamily

All nucleated cells

Antigen presentation
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
View information about HLA-A on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 01/16/2013

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-human HLA-A,B,C

  • FITC anti-human HLA-A,B,C

  • PE anti-human HLA-A,B,C

  • PE/Cyanine5 anti-human HLA-A,B,C

  • Purified anti-human HLA-A,B,C

  • Alexa Fluor® 488 anti-human HLA-A,B,C

  • Alexa Fluor® 647 anti-human HLA-A,B,C

  • Pacific Blue™ anti-human HLA-A,B,C

  • PerCP anti-human HLA-A,B,C

  • APC/Cyanine7 anti-human HLA-A,B,C

  • PerCP/Cyanine5.5 anti-human HLA-A,B,C

  • Ultra-LEAF™ Purified anti-human HLA-A,B,C

  • PE/Cyanine7 anti-human HLA-A,B,C

  • Brilliant Violet 510™ anti-human HLA-A,B,C

  • Alexa Fluor® 700 anti-human HLA-A,B,C

  • PE/Dazzle™ 594 anti-human HLA-A,B,C

  • Biotin anti-human HLA-A,B,C

  • Brilliant Violet 605™ anti-human HLA-A,B,C

  • APC/Fire™ 750 anti-human HLA-A,B,C

  • TotalSeq™-A0058 anti-human HLA-A,B,C

  • TotalSeq™-C0058 anti-human HLA-A,B,C

  • TotalSeq™-B0058 anti-human HLA-A,B,C

  • Spark NIR™ 685 anti-human HLA-A,B,C

  • TotalSeq™-D0058 anti-human HLA-A,B,C

  • GMP Ultra-LEAF™ Purified anti-human HLA-A,B,C SF

  • GMP Ultra-LEAF™ Biotin anti-human HLA-A,B,C SF


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account